54231-44-6

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-chloropyridin-3-yl)morpholine is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(2-chloropyridin-3-yl)morpholine serves as an intermediate in the production of pesticides and other agrochemicals. Its incorporation into these products can enhance their effectiveness in protecting crops and managing pests.
Used in Organic Synthesis:
4-(2-chloropyridin-3-yl)morpholine is utilized as a building block in organic synthesis, enabling the creation of a wide range of organic compounds. Its presence in these reactions can facilitate the formation of complex molecules with specific properties.
Used as a Reagent in Chemical Reactions:
CPYMP is employed as a reagent in various chemical processes, where it can participate in multiple types of reactions, such as substitution, addition, or condensation, to yield desired products with specific functionalities.

Upstream product

• 54231-37-7 4-(2-nitropyridin-3-yl)morpholine 
• 110-91-8 morpholine 
• 78607-36-0 2-chloro-3-iodopyridine 
• 54231-32-2 3-chloro-2-nitropyridine 
• 54231-33-3 3-bromo-2-nitropyridine 
• 54231-34-4 3-iodo-2-nitropyridine 
• 52200-48-3 3-bromo-2-chloropyridine 
• 5765-65-1 4-(benzoyloxy)morpholine 
• 1380288-32-3 C₁₀H₁₃BClNO₂ 

Downstream Products

• 1227173-61-6 N-(4-(3-morpholinopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine 
• 1300645-60-6 4-(2-[4-(3,4-dimethoxypyridin-2-yl)methoxyphenyl]pyridin-3-yl)morpholine 

Relevant academic research and scientific papers

OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS

A compound of Formula I : (I) or a pharmaceutically acceptable salt thereof, wherein: each R' is QR1; each Q is independently selected from a bond, -C1-C10 alkylene, -C2-C10 alkenylene, -C(O)-, -C(O)O-, -C(O)N(R1)-, -C(O)N(R1)SO2- -N(R1)C(O)-, - N(R1)-, -N(SO2(R1)), -N(R1)SO2- -C(O)NR4R5-, -N(R4R5)C(O)-, -N(R4R5)- - S-, -SO-, -SO2-, -S(O)O-, -SO2N(R1)- and -O-; each R1 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 heteroalkyl, aryl, heteroaryl, C3-C10 cycloalkyl, -(C1-C10 alkylene)-C3-C10 cycloalkyl, halogen, cyano, C1-C10 alkylene- aryl, C1-C10 alkylene heteroaryl, C1-C10 heterocycloalkyl and -(C1-C10 alkylene)- C1-C10 heterocycloalkyl. The compounds are inhibitors of HDAC and therefore have potential utility in the therapy of a number of conditions including cancer and inflammation.

Streamlined Synthesis of Diaminopyridines by Pd-Catalyzed Ammonia Coupling with Deactivated Amino-Chloropyridines

An efficient and cost-effective two-step synthesis of diaminopyridines, fundamental building blocks of biologically active compounds, is reported. The advantages over previously reported routes include cost and wider availability of the bromo-chloropyridine starting materials and the straightforward accessibility to an extended array of diaminopyridine regioisomers. The key enabler of this synthetic strategy is the development of an unprecedented palladium-catalyzed coupling reaction of ammonia with chloropyridines deactivated by the presence of an alkylamino substituent. The coupling reaction was accomplished with very low catalyst loadings under remarkably mild reaction conditions, making the system particularly suitable for both academic and industrial applications. The utility of this methodology is exemplified by the application to the synthesis of highly relevant scaffolds, including the synthetic intermediates of the marketed drugs Ribociclib and Palbociclib.

Practical catalytic method for synthesis of sterically hindered anilines

A practical catalytic method for the synthesis of sterically hindered anilines is described. The amination of aryl and heteroaryl boronic esters is accomplished using a catalyst prepared in situ from commercially available and air-stable copper(i) triflat

ARYL AMINOPYRIDINE PDE10 INHIBITORS

The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Study of a new rate increasing "base effect" in the palladium-catalyzed amination of aryl iodides

Evidence for an interphase deprotonation of Pd(II)-amine complexes with weak carbonate base has been gained for the first time. When a rate-limiting deprotonation step is involved in the catalytic cycle, controlling the structure (shape and size of the particles) and/or molar excess of the carbonate base used can significantly increase the reaction rate of Buchwald-Hartwig aminations. By taking such a "base effect" into account a general protocol for the intermolecular amination of aryl iodides with all types of amines has been developed based on a standard Pd-BINAP catalyst, using cesium carbonate as the base.